Literature DB >> 11205591

Successful treatment of scabies with oral ivermectin in Nigeria.

E N Nnoruka1, C E Agu.   

Abstract

Currently, several topical scabicides are available but there is yet no oral or parenteral drug which has been established for the treatment of scabies in Nigeria. Ivermectin which is a modified avermectin, known to be an ectoparasiticidal agent in animals, has been used in adults for systemic parasitosis. In Nigeria, 25% benzyl benzoate is being extensively used for the treatment of scabies in adults. It is effective and readily available. The present study was carried out to evaluate the efficacy and safety of ivermectin in the treatment of patients with scabies at the skin clinic of the University of Nigeria Teaching Hospital, Enugu. Fifty-eight patients with scabies were recruited for the study; 13 (22.4%) were children aged between 5-14 years. Oral ivermectin was given in a single dose of 200 [microg/kg body weight to 29 patients. The remaining 29 patients had to apply 25% benzyl benzoate emulsion. All patients received a full physical and dermatological examination prior to onset of treatment and weekly for 4 weeks. Skin scrapings were taken to confirm the diagnosis of scabies. There was a 93% resolution of pruritus with ivermectin and 48% with benzyl benzoate. No side effects were observed with ivermectin. Our results show that oral ivermectin is a promising, effective and safe alternative in both children and adults of Nigeria when compared to 25% benzyl benzoate topical application.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11205591     DOI: 10.1177/004947550103100105

Source DB:  PubMed          Journal:  Trop Doct        ISSN: 0049-4755            Impact factor:   0.731


  10 in total

Review 1.  Scabies.

Authors:  Prof Paul Johnstone; Mark Strong
Journal:  BMJ Clin Evid       Date:  2008-08-22

2.  Ivermectin worthy of further investigation.

Authors:  Andrew C Steer; Therese Kearns; Ross M Andrews; James S McCarthy; Jonathan R Carapetis; Bart J Currie
Journal:  Bull World Health Organ       Date:  2009-10       Impact factor: 9.408

3.  Ivermectin versus benzyl benzoate applied once or twice to treat human scabies in Dakar, Senegal: a randomized controlled trial.

Authors:  Fatimata Ly; Eric Caumes; Cheick Ahmet Tidiane Ndaw; Bassirou Ndiaye; Antoine Mahé
Journal:  Bull World Health Organ       Date:  2009-06       Impact factor: 9.408

4.  Scabies.

Authors:  Paul Johnstone; Mark Strong
Journal:  BMJ Clin Evid       Date:  2014-12-22

Review 5.  The Treatment of Scabies.

Authors:  Corinna Dressler; Stefanie Rosumeck; Cord Sunderkötter; Ricardo Niklas Werner; Alexander Nast
Journal:  Dtsch Arztebl Int       Date:  2016-11-14       Impact factor: 5.594

Review 6.  Interventions for treating scabies.

Authors:  M Strong; P Johnstone
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18

7.  Scabies: an ancient global disease with a need for new therapies.

Authors:  Jackson Thomas; Greg M Peterson; Shelley F Walton; Christine F Carson; Mark Naunton; Kavya E Baby
Journal:  BMC Infect Dis       Date:  2015-07-01       Impact factor: 3.090

8.  Long Term Control of Scabies Fifteen Years after an Intensive Treatment Programme.

Authors:  Michael Marks; Betty Taotao-Wini; Lorraine Satorara; Daniel Engelman; Titus Nasi; David C Mabey; Andrew C Steer
Journal:  PLoS Negl Trop Dis       Date:  2015-12-01

Review 9.  Therapeutic Potential of Tea Tree Oil for Scabies.

Authors:  Jackson Thomas; Christine F Carson; Greg M Peterson; Shelley F Walton; Kate A Hammer; Mark Naunton; Rachel C Davey; Tim Spelman; Pascale Dettwiller; Greg Kyle; Gabrielle M Cooper; Kavya E Baby
Journal:  Am J Trop Med Hyg       Date:  2016-01-19       Impact factor: 2.345

10.  Prevalence of Scabies and Impetigo 3 Years After Mass Drug Administration With Ivermectin and Azithromycin.

Authors:  Michael Marks; Lucia Romani; Oliver Sokana; Lazarus Neko; Relmah Harrington; Titus Nasi; Handan Wand; Margot J Whitfeld; Daniel Engelman; Anthony W Solomon; John M Kaldor; Andrew C Steer
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.